Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; ReveraGen to research and co-develop vamorolone, a non-hormonal steroid modulator for the treatment of duchenne muscular dystrophy; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase 1 clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland. Show More...
-
Website http://www.idorsia.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 1.64 CHF
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share CHF -2.81 -0.13 -3.1 -3.76 -3.86 Dividends CHF 12.0 Payout Ratio % * Shares Mil 119.0 114.0 125.0 131.0 131.0 Book Value Per Share * CHF 5.71 5.92 2.49 0.41 Free Cash Flow Per Share * CHF -2.28 -0.75 -3.65 Return on Assets % -36.62 -28.64 -40.95 -45.24 Financial Leverage (Average) 1.79 1.73 2.12 5.82 15.22 Return on Equity % -65.42 -54.8 -117.93 -163.38 Return on Invested Capital % -39.94 -32.95 -48.2 -53.88 Interest Coverage -24.18 Current Ratio 11.43 9.46 8.98 6.99 4.25 Quick Ratio 11.09 6.91 7.66 2.46 0.87 Debt/Equity 0.57 0.49 0.86 3.61 10.8